Revolution Medicines, Inc.
Clinical trials sponsored by Revolution Medicines, Inc., explained in plain language.
-
New pill takes on deadly pancreatic cancer in major trial
Disease control OngoingThis phase 3 study tests a new drug, daraxonrasib, against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug or standard thera…
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 08:31 UTC
-
New pill targets hard-to-treat cancers with KRAS mutation
Disease control OngoingThis early-phase study tests a new drug called RMC-6291 in adults with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see how the body handles the drug. About 222 people with lung, colorectal, or pancreatic cancer that has not r…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC